Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial (Q36163205)

12 August 2017

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial (English)

1 reference

12 August 2017

phase II clinical trial

0 references

1 reference

1 reference

10

David Dingli

1 reference

12 August 2017

20

Angela Dispenzieri

1 reference

12 August 2017

5

Martha Q Lacy

1 reference

12 August 2017

18

Stephen J Russell

1 reference

12 August 2017

19

S Vincent Rajkumar

1 reference

12 August 2017

6

Morie A Gertz

1 reference

12 August 2017

2

Suzanne R Hayman

1 reference

12 August 2017

14

Steven R Zeldenrust

1 reference

12 August 2017

16

John A Lust

1 reference

12 August 2017

3

Francis K Buadi

1 reference

12 August 2017

1

Shaji K Kumar

1 reference

12 August 2017

9

Leif P Bergsagel

1 reference

12 August 2017

12

Craig B Reeder

1 reference

12 August 2017

4

Vivek Roy

1 reference

12 August 2017

11

Joseph R Mikhael

1 reference

12 August 2017

15

Philip R Greipp

1 reference

12 August 2017

7

Jacob Allred

1 reference

12 August 2017

8

Kristina M Laumann

1 reference

12 August 2017

Rafael Fonseca

17

0 references

author name string

A Keith Stewart

series ordinal

13

1 reference

PMCID

3418771

12 August 2017

language of work or name

English

0 references

publication date

13 April 2012

1 reference

12 August 2017

1 reference

12 August 2017

119

1 reference

12 August 2017

21

1 reference

12 August 2017

4860-4867

1 reference

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Improved survival in multiple myeloma and the impact of novel therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

International uniform response criteria for multiple myeloma.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

AL amyloidosis: the last 30 years

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Recent major improvement in long-term survival of younger patients with multiple myeloma

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

5 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

5 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418771

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

5 December 2018

1 reference

12 December 2020

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis

1 reference

12 December 2020

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

12 December 2020

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

1 reference

12 December 2020

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

1 reference

12 December 2020

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

1 reference

12 December 2020

10.1182/BLOOD-2012-01-407791

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

PMCID

3418771